Abstract
Objectives: There are no published data regarding efficacy of tigecycline in brucellosis and in vitro data are scarce. We compared the in vitro activity of tigecycline to that of trimethoprim-sulfamethoxazole, rifampicin, tetracycline, streptomycin and ciprofloxacin against Brucella spp. Study Design: In vitro activities of tigecycline, trimethoprim-sulfamethoxazole, rifampicin, tetracycline, streptomycin and ciprofloxacin were evaluated against 96 strains of Brucella spp. Minimal inhibitory concentrations (MIC) were determined by the E-test method. Results: Tigecycline had low MIC50 and MIC90 values against all Brucella isolates; the highest MIC observed was 0.19 µg/mL. Conclusion: Tigecycline had low MICs against Brucella spp. including tetracycline-resistant isolates and its use in therapy should be confirmed by clinical studies. Turkish Başlık: In Vitro Activity of Tigecycline Against Brucella spp. Anahtar Kelimeler: Tigesiklin, Brucella spp Amaç: Brucelloz tedavisinde tigesiklinin in vitro etkinliği ile ilgili bilgi çok fazla bulunmamaktadır. Çalışmamızda Brucella cinsi mikroorganizmalara karşı trimetoprim-sülfametaksazol, rifampisin, tetrasiklin, streptomisin ve siprofloksasin ile tigesiklinin in vitro aktivitesinin karşılaştırılması amaçlanmıştır. Çalışma Planı: Brucella cinsi 96 izolata karşı tigesiklin, trimetoprim-sülfametaksazol, rifampisin, tetrasiklin, streptomisin ve siprofloksasinin in vitro aktivitesi belirlenmiştir. Minimal inhibitör konsantrasyon (MİK) değerleri E-test yöntemiyle saptanmıştır. Bulgular: Tüm Brucella izolatlarına karşı en düşük MİK50 ve MİK90 değerleri tigesiklinde belirlenmiştir. Tigesiklinin en yüksek MİK değeri 0.19 µg/mL olarak saptanmıştır. Sonuç: Tetrasikline dirençli olan izolatlar da dahil olmak üzere Brucella izolatlarına karşı en düşük MİK değeri tigesiklin ile belirlenmiştir. Tigesiklinin tedavide kullanımı klinik çalışmalar ile onaylanmalıdır.
Keywords
References
- Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999;43:1298-300.
- Elfaki MG, Uz-Zaman T, Al-Hokail AA, Nakeeb SM. Detection of Brucella DNA in sera from patients with brucellosis by polymerase chain reaction. Diagn Microbiol Infect Dis 2005;53:1-7.
- Gür D, Kocagöz S, Akova M, Unal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999;43:2337.
- Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibil- ity of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991;35:1925-7.
- Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007;39:432-4.
- Clinical and Laboratory Standards Institute. 2007. M100-S17. Performance standards for antimicro- bial susceptibility testing; 16th informational supple- ment. Clinical and Laboratory Standards Institute, Wayne, PA.
- Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gür D. Quinolones in treatment of human brucel- losis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831-4.
- García-Rodríguez JA, Muñoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993;37:911-3.
- García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995;39:1194-5.
- Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, et al. Biotypes and antimicrobial sus- ceptibilities of Brucella isolates. Scand J Infect Dis 2003;35:337-8.
- Turan H, Arslan H, Azap OK, Serefhanoğlu K, Uncu H. In vitro antibacterial activity of tigecycline in com- parison with doxycycline, ciprofloxacin and rifam- picin against Brucella spp. Int J Antimicrob Agents 2007;30:186-7.
Abstract
Amaç: Brucelloz tedavisinde tigesiklinin in vitro etkinliği
ile ilgili bilgi çok fazla bulunmamaktadır. Çalışmamızda
Brucella cinsi mikroorganizmalara karşı trimetoprimsülfametaksazol,
rifampisin, tetrasiklin, streptomisin ve
siprofloksasin ile tigesiklinin in vitro aktivitesinin karşılaş-
tırılması amaçlanmıştır.
Çalışma Planı: Brucella cinsi 96 izolata karşı tigesiklin,
trimetoprim-sülfametaksazol, rifampisin, tetrasiklin,
streptomisin ve siprofloksasinin in vitro aktivitesi belirlenmiştir.
Minimal inhibitör konsantrasyon (MİK) değerleri
E-test yöntemiyle saptanmıştır.
Bulgular: Tüm Brucella izolatlarına karşı en düşük MİK50
ve MİK90 değerleri tigesiklinde belirlenmiştir. Tigesiklinin
en yüksek MİK değeri 0.19 μg/mL olarak saptanmıştır.
Sonuç: Tetrasikline dirençli olan izolatlar da dahil olmak
üzere Brucella izolatlarına karşı en düşük MİK değeri
tigesiklin ile belirlenmiştir. Tigesiklinin tedavide kullanımı
klinik çalışmalar ile onaylanmalıdır.
Keywords
References
- Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999;43:1298-300.
- Elfaki MG, Uz-Zaman T, Al-Hokail AA, Nakeeb SM. Detection of Brucella DNA in sera from patients with brucellosis by polymerase chain reaction. Diagn Microbiol Infect Dis 2005;53:1-7.
- Gür D, Kocagöz S, Akova M, Unal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999;43:2337.
- Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibil- ity of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991;35:1925-7.
- Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007;39:432-4.
- Clinical and Laboratory Standards Institute. 2007. M100-S17. Performance standards for antimicro- bial susceptibility testing; 16th informational supple- ment. Clinical and Laboratory Standards Institute, Wayne, PA.
- Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gür D. Quinolones in treatment of human brucel- losis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831-4.
- García-Rodríguez JA, Muñoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993;37:911-3.
- García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995;39:1194-5.
- Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, et al. Biotypes and antimicrobial sus- ceptibilities of Brucella isolates. Scand J Infect Dis 2003;35:337-8.
- Turan H, Arslan H, Azap OK, Serefhanoğlu K, Uncu H. In vitro antibacterial activity of tigecycline in com- parison with doxycycline, ciprofloxacin and rifam- picin against Brucella spp. Int J Antimicrob Agents 2007;30:186-7.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | March 1, 2009 |
| Published in Issue | Year 2009 Volume: 2009 Issue: 3 |